Nabsys Showcases OhmX™ Platform's Breakthroughs at ASHG 2025
During the American Society of Human Genetics (ASHG) Annual Meeting, Nabsys 2.0, LLC, a leader in electronic genome mapping technology, demonstrated the capabilities of its innovative OhmX™ Platform. This platform has proven to be instrumental in reliably verifying structural variants in undiagnosed disorders, enhancing the medical community's ability to manage complex genetic conditions.
Collaborative Session with Boston Children's Hospital
In collaboration with Boston Children's Hospital, Nabsys hosted a Google Colaboratory (CoLab) Session. This event highlighted the practical applications of the OhmX™ Platform, showcasing how electronic genome mapping (EGM) can streamline processes in diagnosing rare diseases.
Demonstrating Real-world Impact
At the session, leading experts presented compelling results from recent studies utilizing the OhmX™ Platform. They discussed how integrating this advanced technology with a comprehensive multi-omics strategy can accelerate gene discovery for rare diseases, offering crucial insights into genetic conditions that are challenging to diagnose.
Expert Endorsements
Catherine Brownstein, M.P.H., Ph.D., from Boston Children's Hospital, emphasized the game-changing nature of Nabsys' EGM technology. She noted that it uncovers structural variations that would typically go undetected, greatly enhancing the understanding of the disease mechanisms behind difficult-to-diagnose conditions.
Key Findings and Innovations Presented
Barrett Bready, M.D., founder and CEO of Nabsys, expressed pride in presenting significant advancements at the ASHG meeting. He remarked on the critical aspects of speed, accessibility, and accuracy when exploring whole-genome structural variations. The CoLab session served as a platform to share insights that highlight the transformative impact of the OhmX™ Platform.
Poster Presentation Insights
Nabsys unveiled a poster titled "Accelerated Electronic Genome Mapping with Simultaneous Dual Nicking & Labeling: Boosting Structural Variant Calling on the OhmX Platform". This poster detailed a novel approach that combines simultaneous dual nicking and labeling to streamline EGM sample preparation. The improvements achieved with this technique reduced workflow complexity and significantly enhanced assembly contiguity, yielding a 1.8-fold increase along with a 24% boost in structural variant recall.
The Importance of Streamlined Workflows
Jay Sage, Ph.D., Senior Director of Assay Development at Nabsys, stressed that refining EGM workflows is paramount to minimizing variability and shortening sample-to-answer times. This is particularly essential in urgent situations such as prenatal testing. He noted that these process enhancements not only accelerate results but maintain the integrity of the analyses, offering researchers essential data for understanding disease phenotypes.
Future Directions for Nabsys
The advancements discussed at the ASHG meeting underline Nabsys' commitment to pioneering the next evolution in genomics. With the OhmX™ Platform leading the way, the company is set to further empower researchers in the quest for answers in complex genetic conditions. As Nabsys continues to innovate, it remains dedicated to improving diagnostic processes and enhancing patient outcomes globally.
Frequently Asked Questions
1. What is the OhmX™ Platform?
The OhmX™ Platform by Nabsys is an advanced electronic genome mapping technology designed to verify structural variants in DNA, aiding in the diagnosis of rare diseases.
2. How does Nabsys collaborate with hospitals?
Nabsys partners with hospitals like Boston Children's to implement their technology in clinical settings, providing insights that drive breakthroughs in genetic diagnosis.
3. What improvements have been made to the genome mapping process?
Recent enhancements include the implementation of simultaneous dual nicking and labeling methods, which streamline sample preparation and improve accuracy in variant calling.
4. Why is accurate structural variant identification important?
Identifying structural variants accurately is crucial for understanding the genetic basis of diseases, which facilitates better diagnosis and treatment options for complex disorders.
5. How does Nabsys aim to enhance patient outcomes?
Nabsys focuses on creating cost-effective, accurate genomic analyses that improve diagnostic yields, ultimately leading to better patient management and outcomes.
